Search Results for:
-
Revenue of the Top Biotech Drugs, 2003-2008
Drug name (maker) 2004 2003 1 Enbrel (Amgen) $1,900M (Amgen only) $1,300M (Amgen only) 2 Rituxan (Genentech) $1,574M $1,489M 3 Humira (Abbott) $852M $246M 4 Avastin (Genentech) $545M (U.S.) $--- 5 Herceptin (Genentech) $1,591M $2,064M 6 Remicade (J&J) $2,145M $1,729M 7 Gleevec (Novartis) $1,634M $1,128M 8 Neulasta (Amgen) $1,700M $1,300M 9 Lantus (Sanofi-Aventis) $1,025M $400M (U.S.) 10 Aranesp (Amgen) $2,500M $1,600M 11 Prevnar (Wyeth) $1,036M $946M -
Revenue of the Top Biotech Drugs, 2003-2008
Drug name (maker) 2008 2007 2006 2005 1 Enbrel (Amgen) $5,982M $5,275M $4,379M $3,673M 2 Rituxan (Genentech) $5,082M $5,467M $3,881M $1,831M 3 Humira (Abbott) $4,521M $3,064M $2,044M $1,400M 4 Avastin (Genentech) $4,479M $4,070M $2,380M $1,133M 5 Herceptin (Genentech) $4,394M $4,809M $3,150M $2,416M 6 Remicade (J&J) $3,748M $3,327M $3,014M $2,535M 7 Gleevec (Novartis) $3,700M $3,050M $2,554M $2,170M 8 Neulasta (Amgen) $3,318M $3,000M $2,710M $2 -
Patent Expirations of the Top Biotech Drugs
Drug name (maker) Patent expires Additional dates 1 Enbrel (Amgen) 2009; 2012 2 Rituxan (Genentech) 2015-2018 2013 (outside of U.S.) 3 Humira (Abbott) 2018 4 Avastin (Genentech) 2017; 2019 5 Herceptin (Genentech) 2019 6 Remicade (J&J) 2014 7 Gleevec (Novartis) 2015 8 Neulasta (Amgen) 2015 2006; 2015 (Europe) 9 Lantus (Sanofi-Aventis) 2013-2015 10 Aranesp (Amgen) 2024 2010; 2014 (Europe) 11 Prevnar (Wyeth) 2007; 2012 12 Taxotere (Sanofi-Aventis -
25. Tracleer
Proper Name: Bosentan Type: Cardiovascular antihypertensive Drug Developer: Actelion Ltd. Location: Allschwil/Basel, Switzerland Website: www.actelion.com Indication(s): To treat WHO Class III or IV pulmonary arterial hypertension Approval Date: November 2001 Patent Expires: 2015 2008 Revenue: $1.641 billion Percentage of Actelion's Total Revenue: 87.79 percent Tracleer Treats Pulmonary Arterial Hypertension Pulmonary arterial hypertension (PAH) is a life-threatening condition in -
24. Betaseron
Proper Name: Interferon beta-1b Type: Autoimmune drug Drug Developer: Bayer Schering Pharma Location: Emeryville, California Website: www.bayerhealthcare.com. Indication(s): For the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations Approval Date: August 1993 Patent Expired:2008 2008 Revenue: $1.586 billion Percentage of Bayer Schering's Total Revenue: 3.15 percent History of Betaseron Betaseron has experienced a long and intricate -
23. Cialis
Proper Name: Tadalafil Type: PDE-5 inhibitor Drug Developer: Eli Lilly and Co. Location: Indianapolis, Indiana Website: www.lilly.com Indication(s): For the treatment of male erectile dysfunction (ED): It serves as a temporary aid to male ED patients during sexual activity. Approval Date: November 2003 Patent Expires: 2016 2008 Revenue: $1.445 billion Percentage of Eli Lilly's Total Revenue: 7.09 percent Cialis Has One Specific Task Cialis is an oral medication meant to aid men -
22. Erbitux
Proper Name: Cetuxima Type: Anticancer Drug Developer: ImClone Systems Inc. Location: New York, New York Website: www.imclone.com Indication(s): Colorectal cancer that has spread to other parts of the body in patients whose tumors express an epidermal growth factor receptor; in combination with radiation therapy for head and neck cancer Approval Date: February 2004 Patent Expiration: 2017 2008 Revenue: $1.457 billion Percentage of Eli Lilly's Total Revenue: 7.15 percent Percentage of -
21. Atripla
Proper Name: Efavirenz tenofovir emtricitabine Type: Nucleoside/nucleotide reverse transcriptase inhibitor Drug Developer: Gilead Sciences Inc. Location: Foster City, California Website: www.gilead.com Indication(s): For use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults Approval Date: July 2006 Patent Expires: 2010; 2018 2008 Revenue (Reported by Gilead): $1.570 billion 2008 Revenue Reported by Bristol-Myers -
20. Rebif
Proper Name: Interferon beta-1a Type: Multiple sclerosis therapeutic Developer: Merck Serono SA Location: Geneva, Switzerland Website: www.serono.com Indication(s): Treatment of relapsing multiple sclerosis by way of interferon-specific disease modification, to slow the development of physical disability and decrease flare-up frequency Approval Date: March 2002 Patent Expires: 2017 2008 Revenue: $1.668 billion Percentage of Merck KGaA's Total Revenue: 17.34 percent Rebif, Recent -
19. Humalog
Proper Name: Insulin lispro Type: Insulin diabetes therapeutic Drug Developer: Eli Lilly and Co. Location: Indianapolis, Indiana Website: www.lilly.com Indication(s): For quick-response mealtime management of hyperglycemia in patients with diabetes mellitus Approval Date: June 1996 Patent Expires: 2013 2008 Revenue: $1.736 billion Percentage of Eli Lilly's Total Revenue: 8.52 percent About Humalog, the First Insulin Analog Drug In 1982, Eli Lilly and Co. introduced Humulin. It is -
18. Lucentis
Proper Name: Ranibizumab Type: Vascular endothelial growth factor inhibitor Drug Developer: Genentech Inc. Location: South San Francisco, California Website: www.gene.com Indication(s): Wet age-related macular degeneration Approval Date: July 2006 Patent Expires: 2018 2008 Revenue: $1.761 billion Percentage of Genentech's Total Revenue: 13.14 percent Lucentis Dominates the Wet AMD Market Genentech Inc.'s Lucentis currently dominates the wet age-related macular degeneration (AMD -
17. Truvada
Proper Name: Emtricitabine and tenofovir disoproxil fumarate Type: Anti-HIV Developer: Gilead Sciences Inc. Location: Foster City, California Website: www.gilead.com Indication(s): In combination with other antiretroviral agents for the treatment of HIV-1 infection Approval Date: August 2004 Patent Expires: 2010; 2018 2008 Revenue: $2.110 billion Percentage of Gilead's Total Revenue: 39.54 percent Hero Therapies Needed in Battle Against HIV/AIDS Human immunodeficiency virus (HIV) is -
16. Avonex
Proper Name: Interferon beta-1a Type: Autoimmune disease drug: multiple sclerosis (MS) therapeutic Drug Developer: Biogen Idec Inc. Location: Cambridge, Massachusetts Website: www.biogenidec.com Indication(s): The relapsing form of MS disease and those at high risk to develop MS Approval Date: May 1996 Patent Expires: 2008-2013 ; 2012 (Europe) 2008 Revenue: $2.203 billion Percentage of Biogen Idec's Total Revenue: 53.76 percent Avonex Has a Long History as Therapy for Multiple -
15. Copaxone
Proper Name: Glatiramer acetate Type: Autoimmune disease drug: multiple sclerosis therapeutic Drug Developer: Teva Neuroscience Inc. Location: Kansas City, Missouri Website: www.tevaneuroscience.com Indication(s): For the reduction of relapses in relapsing-remitting multiple sclerosis Approval Date: December 1996 Patent Expires: 2014; 2015 (most non-U.S. countries) 2008 Revenue: $2.262 billion Percentage of Teva's Total Revenue: 20.41 percent About Multiple Sclerosis, an Autoimmune -
14. Epogen
Proper Name: Epoetin alpha Type: Antianemic Drug Developer: Amgen Inc. Location: Thousand Oaks, California Website: www.amgen.com Indication(s): To treat anemia in patients with chronic renal failure who are on dialysis Approval Date: June 1989 Patent Expires: 2004, 2012, 2013, 2015 2008 Revenue: $2.456 billion Percentage of Amgen's Total Revenue: 16.37 percent Epogen Provides Anti-Anemia Therapy to Renal Dialysis Patients Epogen is an exact copy of naturally produced erythropoietin -
13. Procrit/Eprex
Proper Name: Epoetin alpha Type: Antianemic Drug Developer: Ortho Biotech Products LP Location: Bridgewater, New Jersey Website: www.orthobiotech.com Indication(s): Procrit (in the U.S.): To treat chemotherapy-related anemia in cancer patients; to treat zidovudine (AZT)-related anemia in HIV patients; as a blood transfusion alternative for adults about to undergo elective surgery (excluding cardiac and vascular surgery) Eprex (outside the U.S.): To treat anemia and reduce the need for a -
12. Taxotere
Proper Name: Docetaxel Type: Anticancer Drug Developer: Sanofi-Aventis Group Location: Paris, France Website: www.sanofi-aventis.com Indication(s): For the treatment of locally advanced or metastatic breast cancer after failure of prior anthracycline chemotherapy; locally advanced or metastatic non-small-cell lung cancer (NSCLC); first-line therapy in combination with cisplatin for unresectable, locally advanced or metastatic NSCLC; hormone-refractory metastatic prostate cancer; in -
11. Prevnar
Proper Name: Pneumococcal polysaccharide vaccine Type: Vaccine Drug Developer: Wyeth Location: Madison, New Jersey Website: www.wyeth.com Indication(s): Prevention of diseases caused by Streptococcus pneumoniae (pneumococcus) Approval Date: February 2000 Patent Expires: 2007; 2012 2008 Revenue: $2.716 billion Percentage of Wyeth's Total Revenue: 11.89 percent A Confluence of Dynamics Spells Success If treating is the Alpha aim of medicine, curing is the Omega objective, societal -
10. Aranesp
Proper Name: Darbepoetin alpha Type: Antianemic Drug Developer: Amgen Inc. Location: Thousand Oaks, California Website: www.amgen.com Indication(s): To treat anemia associated with chronic renal failure and to treat chemotherapy-induced anemia in patients with nonmyeloid malignancies Approval Date: September 2001 Patent Expires: 2024; 2010, 2014 (Europe) 2008 Revenue: $3.137 billion Percentage of Amgen's Total Revenue: 20.91 percent Aranesp History and Approvals Amgen Inc.'s -
9. Lantus
Proper Name: Insulin glargine (rDNA origin) Type: Long-acting insulin diabetes therapeutic Developer: Sanofi-Aventis Group Location: Paris, France Website: www.sanofi-aventis.com Indication(s): Adults with Type II diabetes; adults and children with Type I Approval Date: April 2000 Patent Expires: 2013-2015 2008 Revenue: $3.159 billion Percentage of Sanofi-Aventis' Total Revenue: 9.02 percent Lantus Is the Leading Biotech Therapy for Diabetes There are about 230 million people with